Back to Search
Start Over
Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.
- Source :
-
Gynecologic oncology [Gynecol Oncol] 2018 Jan; Vol. 148 (1), pp. 5-11. Date of Electronic Publication: 2017 Dec 06. - Publication Year :
- 2018
-
Abstract
- A 36-year-old with metastatic and refractory choriocarcinoma following single- and multi-agent chemotherapy and surgical metastectomy experienced a durable remission after receiving therapy with an anti-endoglin monoclonal antibody and bevacizumab. Treatment options and scientific advances in this disease are highlighted.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Antibodies, Monoclonal administration & dosage
Bevacizumab administration & dosage
Choriocarcinoma immunology
Choriocarcinoma pathology
Choriocarcinoma surgery
Endoglin antagonists & inhibitors
Endoglin immunology
Female
Gestational Trophoblastic Disease drug therapy
Gestational Trophoblastic Disease pathology
Gestational Trophoblastic Disease surgery
Humans
Pregnancy
Remission Induction
Uterine Neoplasms immunology
Uterine Neoplasms pathology
Uterine Neoplasms surgery
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Choriocarcinoma drug therapy
Uterine Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1095-6859
- Volume :
- 148
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Gynecologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 29217138
- Full Text :
- https://doi.org/10.1016/j.ygyno.2017.11.029